FDA Approved: OGIVRI — Original Application (Biocon Biologics Inc.)

View source ↗

Summary

The FDA approved OGIVRI (trastuzumab-dkst) from Biocon Biologics as a biosimilar to trastuzumab through Biocon's Original Application. It is indicated for HER2-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• OGIVRI (trastuzumab-dkst)

Snippet

ORIG AP for OGIVRI (TRASTUZUMAB-DKST)